Sotera Health Co (SHC) Q1 2026 Earnings Call Transcript

Why It Matters

The raised outlook signals stronger demand for sterilization and testing services, enhancing Sotera’s earnings visibility and cash‑flow generation. Lower leverage and higher liquidity position the company to fund growth initiatives and weather market volatility.

Key Takeaways

• Revenue up 6.4% YoY to $294M, constant currency growth 6%
• Adjusted EBITDA rose 9.8% to $151M, margin 51.2%
• Sterigenics revenue +10.5% driven by volume, mix, pricing
• Nelson Labs margin improved 514 bps despite 3.3% revenue dip
• Guidance raised: 2025 revenue growth 4.5‑6%, EBITDA 6‑7.5%

Pulse Analysis

Sotera Health operates at the intersection of medical‑device sterilization, radiopharmaceutical production, and laboratory testing, markets that have benefited from heightened regulatory scrutiny and post‑pandemic demand for safe medical supplies. Sterigenics, the company’s sterilization arm, leverages ethylene‑oxide and cobalt‑60 technologies to serve device manufacturers, while Nordion supplies radioactive isotopes for sterilization and cancer treatment. Nelson Labs provides compliance testing and advisory services that are essential for FDA approvals. Across the sector, customers are seeking integrated solutions that reduce time‑to‑market, creating a tailwind for providers that can combine high‑volume processing with specialized expertise.

In the second quarter, Sotera delivered $294 million in revenue, a 6.4% increase, and adjusted EBITDA of $151 million, lifting the margin to 51.2%—the highest on record for the firm. Sterigenics contributed $195 million, driven by a 10.5% revenue jump fueled by volume growth, mix improvements, and modest price hikes. Nelson Labs, despite a 3.3% revenue dip, expanded its segment margin by more than 500 basis points through pricing power and productivity gains. The company’s balance sheet strengthened, with liquidity reaching $918 million and net leverage improving to 3.5×, supporting its aggressive capital‑return strategy.

Management’s decision to raise the 2025 revenue outlook to 4.5‑6% and adjusted EBITDA growth to 6‑7.5% reflects confidence in sustained demand and operating leverage. A trimmed 2025 capex range of $170‑$180 million, coupled with a $110 million spend in 2026, should free up cash flow, targeting $500‑$600 million of free cash between 2025 and 2027. Risks remain, including potential disruptions to cobalt‑60 supply and the modest decline projected for Nelson Labs’ advisory services. Nonetheless, the combination of higher margins, deleveraging progress, and a robust pipeline positions Sotera as a compelling play for investors focused on healthcare‑infrastructure growth.